XPA Gene

title: XPA Gene

XPA

Introduction

Xpa Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-gene">

| Property | Value |
|----------|-------|
| Gene Symbol | XPA |
| Full Name | XPA DNA Repair Endonuclease |
| Chromosomal Location | 9q34.3 |
| NCBI Gene ID | 7508 |
| OMIM ID | 278700 |
| Ensembl ID | ENSG00000136936 |
| UniProt ID | P18077 |
| Encoded Protein | DNA repair protein XPA |
| Associated Diseases | Xeroderma pigmentosum, neurodegeneration |

</div>

Overview

title: XPA Gene

XPA

Introduction

Xpa Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-gene">

| Property | Value |
|----------|-------|
| Gene Symbol | XPA |
| Full Name | XPA DNA Repair Endonuclease |
| Chromosomal Location | 9q34.3 |
| NCBI Gene ID | 7508 |
| OMIM ID | 278700 |
| Ensembl ID | ENSG00000136936 |
| UniProt ID | P18077 |
| Encoded Protein | DNA repair protein XPA |
| Associated Diseases | Xeroderma pigmentosum, neurodegeneration |

</div>

Overview

XPA is a gene involved in various cellular processes. The encoded protein plays important roles in metabolism, cellular signaling, and disease pathogenesis.

Function

XPA encodes a zinc-finger protein essential for nucleotide excision repair (NER). XPA recognizes and verifies DNA damage, facilitating repair of UV-induced lesions and chemical adducts.

Key functions include:

• DNA damage recognition in NER
• Verification of DNA lesion
• Recruitment of TFIIH complex
• Incision of damaged strand
• DNA repair coordination

Disease Associations

Xeroderma Pigmentosum (XP)

XPA mutations cause XP complementation group A, characterized by:

• Extreme UV sensitivity
• High risk of skin cancers
• Neurological degeneration (in some patients)
• Progressive neurodegeneration

Neurodegeneration

XPA deficiency leads to neurodegeneration through:

• Accumulation of DNA damage
• Transcriptional defects
• Mitochondrial dysfunction
• Oxidative stress

Expression

XPA is expressed in:

• Brain ([neurons](/entities/neurons), glia)
• Skin
• Most proliferating cells
• High in neural tissue

Protein Structure

The XPA protein (∼297 amino acids, ∼32 kDa) contains several functional domains:

• N-terminal region: Contains the DNA-binding domain that recognizes damaged DNA
• Central region: Facilitates protein-protein interactions with other NER factors
• C-terminal region: Contains the nuclear localization signal (NLS) and binding sites for replication protein A (RPA)

Mechanism in Nucleotide Excision Repair

XPA plays multiple critical roles in the NER pathway:

Role in Neurodegeneration

Alzheimer's Disease

In AD, accumulating evidence suggests that NER efficiency declines with age and in disease states. Reduced XPA expression and activity may contribute to:

• Accumulation of oxidative DNA damage in [neurons](/entities/neurons)
• Impaired transcription of critical neuronal genes
• Accelerated neuronal death

Parkinson's Disease

DNA damage in dopaminergic neurons is a hallmark of PD. XPA dysfunction may:

• Exacerbate mitochondrial DNA damage
• Impair repair of oxidatively-induced DNA lesions
• Contribute to progressive dopaminergic neuron loss

Xeroderma Pigmentosum-Neurodegeneration

XP patients with XPA mutations who survive to adulthood often develop progressive neurodegeneration, providing a human model for XPA's role in maintaining neuronal health.

Background

The study of Xpa Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Cross-links

• [DNA Repair](/mechanisms/dna-repair-pathways)
• [Nucleotide Excision Repair](/mechanisms/nucleotide-excision-repair)
• [Transcription-Coupled Repair](/mechanisms/transcription-coupled-repair)
• [Global Genome NER](/mechanisms/global-genome-ner)
• [Xeroderma Pigmentosum](/diseases/xeroderma-pigmentosum)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
• [Oxidative Stress](/mechanisms/oxidative-stress)
• [DNA Damage Response](/mechanisms/dna-damage-response)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Aging](/mechanisms/cellular-aging)
• [TFIIH Complex](/proteins/gtf2h1)
• [ERCC1 Gene](/genes/ercc1)
• [RPA Complex](/proteins/rpa1)
• [XPG Gene](/genes/xpg)

Role in Normal Cellular Physiology

Transcriptional Coupling

XPA plays a crucial role in coupling NER to transcription through its interactions with RNA polymerase II:

• Transcription-Coupled Repair (TCR): XPA is recruited to actively transcribed genes to repair lesions that block elongating RNA polymerase II
• Global Genome NER (GG-NER): XPA verifies damage in non-transcribed regions and throughout the genome
• Repair Synthesis: Following lesion verification, XPA helps coordinate DNA polymerase δ and ε for gap-filling synthesis

Protein-Protein Interactions

XPA interacts with numerous key proteins in the NER machinery:

| Partner Protein | Interaction Domain | Functional Consequence |
|-----------------|-------------------|----------------------|
| RPA | C-terminal | DNA damage recognition and stabilization |
| TFIIH | Central region | Lesion verification and strand opening |
| ERCC1 | C-terminal | 5' incision coordination |
| XPG | Central region | 3' incision coordination |
| p53 | N-terminal | Transcription regulation and apoptosis |

Cellular Localization and Regulation

XPA is primarily nuclear and its expression is regulated at multiple levels:

• Transcriptional Regulation: XPA expression is induced by p53 in response to DNA damage
• Post-translational Modifications: Phosphorylation affects XPA's DNA binding and protein interactions
• Cell Cycle Dependence: XPA levels vary throughout the cell cycle, peaking in S-phase

XPA in Neurodegeneration

Alzheimer's Disease Pathogenesis

In Alzheimer's disease, accumulating evidence points to impaired NER including XPA dysfunction:

DNA Damage Accumulation: Neurons in AD brain show elevated levels of oxidative DNA lesions, including cyclobutane pyrimidine dimers (CPDs) and 6-4 photoproducts [@martin2008]. Reduced XPA activity may contribute to this accumulation.

Epigenetic Dysregulation: Proper NER is required for transcription-coupled repair of DNA damage in actively expressed genes. Impaired XPA function may lead to transcriptional defects in critical neuronal genes, including those involved in amyloid processing and tau phosphorylation.

Mitochondrial DNA Repair: While XPA primarily functions in nuclear NER, there is evidence for mitochondrial targeting in neurons under stress conditions [@xpa2017]. Mitochondrial DNA damage accumulation contributes to neuronal energy deficits in AD.

Therapeutic Implications: Enhancing NER capacity through XPA upregulation represents a potential therapeutic approach:

• Poly(ADP-ribose) polymerase (PARP) inhibitors may enhance NER efficiency
• Antioxidants can reduce oxidative DNA damage burden
• Small molecules that stabilize XPA-DNA complexes may improve repair

Parkinson's Disease

Dopaminergic neurons in the substantia nigra are particularly vulnerable to DNA damage due to:

• High metabolic demand and mitochondrial activity
• Oxidative stress from dopamine metabolism
• Environmental neurotoxins that form DNA adducts

• Accumulation of mutagenic DNA lesions in nuclear and mitochondrial DNA
• Impaired repair of dopaminergic neuron-specific stress
• Enhanced sensitivity to environmental neurotoxins like MPTP and rotenone

Aging and Senescence

Aging is associated with progressive decline in NER capacity:

• XPA protein levels decrease with age in brain tissue [@nerautal2019]
• Reduced NER efficiency contributes to age-related neurodegeneration
• Accelerated aging phenotypes in NER-deficient mouse models
• Cellular senescence driven by DNA damage accumulation

Animal Models and Experimental Evidence

Mouse Models

XPA-deficient mice exhibit:

• Increased susceptibility to UV-induced skin tumors
• Progressive neurodegeneration with age
• Impaired learning and memory
• Accelerated aging phenotype
• Increased incidence of spontaneous tumors

Cell Culture Studies

In vitro studies demonstrate:

• XPA knockdown increases sensitivity to UV and chemical mutagens
• XPA overexpression enhances DNA repair capacity
• Neural progenitor cells require functional XPA for proper differentiation
• Mitochondrial dysfunction in XPA-deficient neurons

Clinical Significance

Xeroderma Pigmentosum (XP)

XP complementation group A (XP-A) is caused by biallelic mutations in the XPA gene:

• Spectrum of Mutations: Over 30 pathogenic variants identified
• Phenotypic Variability: Ranges from severe (childhood neurodegeneration) to mild
• Genotype-Phenotype Correlation: Certain mutations associated with neurological degeneration
• Carrier Status: Heterozygotes may have increased cancer risk

Cancer Predisposition

Beyond XP, XPA polymorphisms may influence:

• Susceptibility to UV-induced skin cancers
• Response to DNA-damaging chemotherapy
• Individual variation in DNA repair capacity
• Risk of other environmental cancers

Diagnostic and Therapeutic Applications

Biomarker Potential

XPA expression and activity may serve as:

• A biomarker for NER capacity in individuals
• A predictor of neurotoxicity risk from chemotherapy
• A monitoring tool for therapeutic intervention efficacy

Therapeutic Development

Strategies targeting XPA and NER:

• Gene Therapy: Viral vector delivery of functional XPA
• Small Molecule Enhancers: Compounds that upregulate XPA expression
• Combination Therapies: NER enhancement with antioxidants
• Personalized Medicine: Genotyping for XPA variants in treatment decisions

Therapeutic Implications

Enhancing NER capacity, including XPA function, represents a potential therapeutic strategy for:

• Aging-related neurodegeneration: Small molecules that upregulate NER proteins
• AD prevention: Antioxidants that reduce DNA damage burden
• PD neuroprotection: Mitochondrial-targeted DNA repair enhancers
• XP treatment: Gene therapy approaches to restore XPA function

See Also

• [Genes Index](/genes-index)
• [Mitochondrial Genes](/genes-index)
• [Neurodegeneration](/diseases/neurodegeneration)

External Links

• [NCBI Gene - XPA](https://www.ncbi.nlm.nih.gov/gene/7508)
• [OMIM - XPA](https://www.omim.org/entry/611153)
• [UniProt - XPA](https://www.uniprot.org/uniprot/P23297)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving XPA Gene discovered through SciDEX knowledge graph analysis: